Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
ISTH Webinar: Inhibitors in Hemophilia
Tell a Friend About This EventTell a Friend
ISTH Webinar: Inhibitors in Hemophilia

9/4/2019
When: Wednesday, September 4, 2019
8:00 AM

« Go to Upcoming Event List  

Inhibitors in Hemophilia

 

September 4, 2019 12:00 - 13:00 UTC

Speakers:

Samantha Gouw "Risk factors, biomarkers and other predictors"

Rolf Ljung "Management of patients with inhibitors"

  • To make an individualized choice of treatment for patients who have developed inhibitors in hemophilia A and B.

Moderator: Karin Fijn van draat

 

Click here to register.

 

Biographies

Samantha Gouw

Samantha C. Gouw, MD, PhD received her PhD doctorate on the etiology of inhibitor development in children with severe hemophilia A (Utrecht University in 2011). In collaboration with a team of international colleagues, she published several papers in Blood and a paper in New England Journal of Medicine on genetic and non-genetic risk factors of inhibitor development. She trained as a pediatric hematologist and clinical epidemiologist. She currently works at the Department of Pediatric Hematology at the Amsterdam University Medical Center and as the coordinating researcher of a nationwide study in hemophilia patients at the Department of Clinical Epidemiology at Leiden University Medical center, The Netherlands. Her current research focuses on inhibitor development in hemophilia and the quality of hemophilia care. 

Rolf C. R. Ljung

Rolf C. R. Ljung, MD, PhD, is currently Senior Professor of Paediatrics at Lund University in Sweden and until recently Senior Consultant in Paediatric Haematology at the Department of Paediatrics, Skåne University Hospital, Malmö and Lund, and at the Malmö Haemostasis and Thrombosis Centre. He received his medical degree from Lund University. Dr Ljung’s research work has been in the field of coagulation, focusing in particular on genetic, molecular biological, and clinical studies in hemophilia. 

Dr Ljung is Chairman of the Management Board of the PedNet Haemophilia Research Foundation (PedNet) and was 2006-2016 scientific chairman of the International Network on Pediatric Hemophilia (INPH). He also is Co-Chairman of the International Prophylaxis Study Group (IPSG). Dr Ljung is a member of the editorial board of Haemophilia and the editorial committee of Acta Paediatrica. He has published numerous papers in professional journals and abstracts in the proceedings of international or national scientific congresses.

Karin Fijn  van Draat

Karin Fijnvandraat (name on publications) is Professor of Pediatric Hematology at the University of Amsterdam and consultant pediatric hematologist in Emma Children’s Hospital, at the Academic Medical Center in Amsterdam. She trained in Pediatrics and specialized in Pediatric Hematology at the University of Amsterdam. Her clinical focus is on hemophilia, allied bleeding disorders and sickle cell disease. After a fellowship in clinical epidemiology, her research focused on inhibitor development in patients with moderate and mild hemophilia A (MHA). In 2008 she initiated the INSIGHT consortium with 34 participating Hemophilia Treatment Centers from 10 European countries and Australia. The results of the studies performed within this consortium shed light on the morbidity, mortality and risk factors of inhibitor development in MHA. Another project within this consortium, the RISE study, addresses the determinants of DDAVP response. Furthermore, she contributed to several multicenter studies in hemophilia, von Willebrand disease and sickle cell disease.

EVENT PHOTOS
Membership Management Software Powered by YourMembership  ::  Legal
This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.